Sorafenib (brand name Nexavar) / JAK2 Cancer Research Results

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱
Features: kinase inhibitor drug

Sorafenib (brand: Nexavar) — an oral multikinase inhibitor targeting RAF kinases and multiple receptor tyrosine kinases (VEGFR-1/2/3, PDGFR-β, FLT3, KIT, RET). Approved for advanced hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), and differentiated thyroid carcinoma (DTC).

Primary mechanisms (conceptual rank):
1) RAF (CRAF/BRAF) inhibition → ↓ MAPK/ERK signaling
2) VEGFR/PDGFR blockade → anti-angiogenesis
3) Induction of mitochondrial apoptosis (Mcl-1↓; caspases↑)
4) Metabolic/redox stress modulation (ROS shifts; ferroptosis sensitization reported)
5) Tumor microenvironment effects (vascular normalization / hypoxia interplay)

Bioavailability / PK relevance: Oral; variable absorption; highly protein-bound; metabolized mainly by CYP3A4 and UGT1A9; half-life ~25–48 h. Achievable plasma levels are within low-micromolar range.

In-vitro vs oral exposure: Many mechanistic studies use concentrations within or slightly above clinical plasma range; off-target cytotoxicity typically at higher doses.

Clinical evidence status: FDA-approved for HCC, RCC, DTC; established survival benefit in advanced disease (modest median OS improvement).

Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.

Sorafenib (Nexavar) — Cancer vs Normal Cell Pathway Map

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 RAF → MEK → ERK (MAPK) ↓ (primary) ↔ / ↓ (proliferating cells) R/G Reduced proliferative signaling Core intracellular target; inhibits CRAF and wild-type BRAF (not selective for BRAF V600E like vemurafenib).
2 VEGFR / PDGFR (angiogenesis) ↓ tumor vascularization ↓ endothelial proliferation R/G Anti-angiogenic effect Major driver of clinical efficacy in HCC/RCC; affects tumor microenvironment.
3 Intrinsic apoptosis (Mcl-1↓, caspases↑) ↑ ↔ / ↑ (dose-dependent) R/G Mitochondrial apoptosis Mcl-1 downregulation is characteristic; enhances chemosensitivity in some models.
4 ROS ↑ (dose-dependent) ↔ / ↑ (high exposure) P/R Oxidative stress contribution Redox stress may contribute to cytotoxicity and resistance mechanisms.
5 Ferroptosis ↑ (context-dependent) ↔ R/G Lipid peroxidation vulnerability Reported to sensitize HCC cells to ferroptosis via system Xc⁻ / SLC7A11 modulation.
6 PI3K/AKT/mTOR ↓ (secondary; model-dependent) ↔ R/G Reduced survival signaling Often compensatory pathway in resistance; combination target in trials.
7 HIF-1α ↓ (anti-angiogenic coupling) ↔ G Reduced hypoxia signaling Indirect via vascular effects; hypoxia may paradoxically increase in resistant tumors.
8 NRF2 ↑ (resistance-associated; context-dependent) ↔ R/G Adaptive antioxidant response NRF2 upregulation linked to sorafenib resistance in HCC.
9 Ca²⁺ signaling ↔ (stress-related) ↔ P/R Not primary axis Secondary to mitochondrial stress; not direct target.
10 Clinical Translation Constraint ↓ (constraint) ↓ (toxicity) — Resistance + tolerability limits Common AEs: hand-foot skin reaction, hypertension, diarrhea; resistance frequent via MAPK reactivation or NRF2 upshift.

TSF legend:
P: 0–30 min (kinase inhibition onset)
R: 30 min–3 hr (signaling cascade suppression)
G: >3 hr (gene regulation, angiogenesis suppression, apoptosis)
JAK2, Janus kinase 2: Click to Expand ⟱
Source: CGL-Driver Genes
Type: Oncogene
A tyrosine kinase that plays a crucial role in the signaling pathways of various cytokines and growth factors. It is particularly important in hematopoiesis (the formation of blood cells) and immune responses.

JAK2 plays a significant role in cancer biology, particularly in hematological malignancies, where its expression and activity are often upregulated. Increased JAK2 activity is generally associated with worse prognosis in many cancers, indicating its potential role in promoting tumor growth and survival.
Scientific Papers found: Click to Expand⟱
5892- CAR,  SRF,    Carvacrol potentiates immunity and sorafenib anti-cancer efficacy by targeting HIF-1α/STAT3/ FGL1 pathway: in silico and in vivo study
- in-vivo, HCC, NA
Hif1a↓, AFP↑, hepatoP↑, STAT3↓, JAK2↓, *CD8+↑, ChemoSen↑, Dose↝, angioG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

STAT3↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 1,  

Immune & Inflammatory Signaling ⓘ

JAK2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,  

Clinical Biomarkers ⓘ

AFP↑, 1,  

Functional Outcomes ⓘ

hepatoP↑, 1,  
Total Targets: 8

Pathway results for Effect on Normal Cells:


Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: JAK2, Janus kinase 2
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:16  Target#:164  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page